Todd Chappell, MBA has experience running multiple drug development programs from discovery stage through to clinical trials. He also has experience working as an EIR at NIH and spent some time working in biotech venture capital, running a portfolio company that was acquired by Tetralogic Pharmaceuticals after bringing a lead compound to clinical trials.
|
Suresh Singh, PhD established the computational design group at Vitae Pharmaceuticals, which was acquired by Allergan, using SILCS technology. At Vitae he launched 7 drug development programs, 6 of which went to clinical trials. Most recently he served as Vice President of Computational Sciences at Hotspot Therapeutics, which recently raised a $45M series A financing.
|
Sunhwan Jo, PhD has been head of Commercial Development at SilcsBio for four years where he was responsible for developing and maintaining the SILCS software platform. Dr. Jo specializes in chemical informatics, machine learning and drug discovery software development.
|
|
National Science Foundation |
© 2021 Rasio All Rights Reserved
